Check out our latest industry white papers. Browse now!
Sales & Support: +1 800 762 3361
Member Resources

BEIJING--September 8, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--China's Tier 2 pharmaceutical contract development and manufacturing companies (CDMOs) have the opportunity to leap to Tier 1 status as more Pharmaceutical & Biotech companies in the West outsource their services, and as China sees the benefits of its Marketing Authorization Holder (MAH) pharmaceutical regulatory system. Tier 2 CDMOs have annual revenue of up to US$500 million, while Tier 1 CDMOs have revenue of more than $US500 million.

Login or Register for Instant Access

Subscribe Now!

(All Fields Required)

All Members Receive the Vlauable Resources

All Members Receive the Following Resources:

  • Industry News Digest
  • Upcoming Podcasts
  • On-Demand Podcasts
  • Economic Indicators
View All Member Resources
IIR Logo Globe

Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.

×
×

Contact Us

For More Info!